J001X

Drug Profile

J001X

Latest Information Update: 14 Dec 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pierre Fabre
  • Class Glycolipids; Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 05 Oct 2001 No Development Reported - Phase-III Inflammation (diagnosis) in France (Inhalation)
  • 16 May 2001 Pierre Fabre has merged with bioMérieux Alliance
  • 20 Feb 1997 Phase-III clinical trials for Inflammation (diagnosis) in France (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top